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OBJECTIVES We investigated immunoreactive von Willebrand factor (vWF), a platelet adhesion molecule,
in the endocardial endothelium and its relationship to thrombogenesis in the human atrial
appendage.
BACKGROUND Intra-atrial thrombogenesis is generally thought to be induced by blood stasis in the atrial
appendage involved with atrial fibrillation (AF). Little attention has been paid to alterations
of the endocardial endothelium on which the thrombus develops.
METHODS Atrial appendage tissue was obtained at heart surgery or at autopsy from AF and non-AF
cardiac patients and from noncardiac patients. Immunohistochemistry for endothelial cell
markers including vWF, CD31, CD34 and endothelial nitric oxide synthase (eNOS) and
platelet glycoprotein Ib/IX or IIb/IIIa was performed and semiquantitatively graded.
RESULTS In contrast to the apparent immunostaining for CD31, CD34 and eNOS, only focal or little
immunoreactive vWF was seen in the endocardium of noncardiac patients. Immunoreactive
vWF in the endocardial endothelium was increased in most cardiac patients, particularly in
the left, but not in the right, atrial appendage of patients with mitral valvular disease,
irrespective of whether AF was present. Platelet adhesion/thrombus formation in the
endocardium was found in limited sites in which the overlying endothelium was deficient in
eNOS and CD34. When warfarin-treated cases were excluded, there was a significant
correlation between the immunohistochemical grade for vWF and the degree of platelet
adhesion/thrombus formation in the endocardium.
CONCLUSIONS Immunoreactive vWF in the endocardial endothelium was increased in overloaded human
atrial appendage, which may be a local predisposing factor for intraatrial thrombogenesis.
(J Am Coll Cardiol 2001;37:1436–42) © 2001 by the American College of Cardiology
Intra-atrial thrombus formation in patients with atrial
fibrillation (AF) is known to be a potent risk factor for
thromboembolic events such as stroke (1). Thrombus for-
mation is preferentially found in the atrial appendage and
has been thought to be induced by blood stasis associated
with AF (2,3). However, the incident rates of cardioembolic
complications have been reported to vary among AF pa-
tients depending on the presence of coexistent heart diseases
and clinical risk factors for thromboembolism, including
age, hypertension, diabetes mellitus and previous ischemic
attack (4,5). In addition, in patients with AF alone who
were ,65 years old, the incident rate of stroke was similar
to that in people without AF (,1%/year for both) (4–6).
Little attention has been paid to alterations of the
endocardial surface on which intra-atrial thrombus develops
(2,3). Platelet adhesion to the deendothelialized vessel wall
is an initiating event of thrombus formation (7) and is
mediated through the platelet adhesion molecule von Wil-
lebrand factor (vWF) present in the plasma and/or suben-
dothelium (8–10). von Willebrand factor is synthesized and
stored in endothelial cells and platelets and can be secreted
locally at the site of injured vessels (11). Recently, elevated
plasma or endothelial levels of vWF have been shown in
pulmonary hypertension (12), congestive heart failure (13)
and chronic AF (14), implying the possible role of vWF in
the thrombotic predilection of these hemodynamic abnor-
malities. Therefore, we have speculated that altered expres-
sion of vWF in the endocardial endothelium may affect local
thrombogenicity in the human atrial appendage.
We examined immunoreactive vWF in the endocardial
endothelium of atrial appendages of AF and non-AF
patients with a variety of underlying cardiac pathogeneses
and compared the data with those of noncardiac patients
without any clinical predictors for thromboembolic risk. In
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addition, to explore the possible role of vWF in thrombo-
genesis, we investigated the relationship between immuno-
reactive vWF in the endocardium and platelet adhesion/
thrombus formation detected at the tissue level.
METHODS
Patients. This study was performed with the permission of
the Ethics Committee for clinical and experimental inves-
tigations at Tohoku University. Atrial appendages were
obtained at heart surgery from patients with mitral (n 5 15)
or aortic valvular disease (n 5 11), coronary artery disease
(n 5 6) and atrial septal defect (n 5 7), and at autopsy
(within 3 h after death) from patients with end-stage heart
failure (n 5 4) and noncardiac patients (seven men/three
women, average age 59 6 5.1 years) with no clinical
high-risk predictors for thromboembolism (4,5). The clin-
ical data of cardiac patients are shown in Table 1. Although
most patients with valvular heart disease had one or more
episodes of congestive heart failure, heart surgery was
performed in a well-controlled condition showing nearly
normal ranges for the cardiac index and left ventricular
ejection fraction. Atrial fibrillation accompanied 12 of 15
patients with mitral valvular disease, but only four of 28
other cardiac patients. Two patients with valvular heart
disease had a history of cerebral infarction, which was
confirmed by a computed tomographic scan of the head.
Full-dose warfarin and/or low-dose aspirin were adminis-
tered in 10 of 15 patients with mitral valvular disease and in
nine of 16 patients with AF. These antithrombotic drugs
were usually discontinued three days before heart surgery.
Both right and left atrial appendages were obtained from
some operative cases that received Maze operation and from
all autopsy cases. Only the right atrial appendage was
available in the other cases.
Immunohistochemistry. Isolated atrial tissue was imme-
diately fixed in 4% paraformaldehyde for 6 h at room
temperature. The tissue was sectioned every 3 mm to survey
the immunoreactivity for vWF and platelet adhesion/
thrombus formation in the endocardium. Immunohisto-
chemistry was performed in cryostat sections (4 mm thick)
by the avidin-biotin-immunoperoxidase method as previ-
ously described (15). Briefly, sections were incubated serially
with the following solutions: 1) 2% hydrogen peroxide for
30 min to block endogenous peroxidase activity; 2) 0.3%
Triton-X 100 for 15 min to permeabilize the membrane; 3)
10% normal goat serum for 60 min to reduce nonspecific
binding of the antiserum; 4) primary antisera for 16 h at
4°C; 5) biotinylated goat antimouse or goat antirabbit
immunglobulin G (IgG) at a dilution of 1:200 for 45 min;
and 6) avidin-biotinylated horseradish peroxidase complex
(Vectastain, Vector Laboratories, Burlingame, California) at
a dilution of 1:100 for 45 min. Immunoreactive sites were
visualized by incubation with 0.025% 3,3-diaminobenzidine
and 0.01% hydrogen peroxide for 3 min. Phosphate-
buffered saline (pH 7.4) was used to dilute each solution and
to wash the sections three times between each step. Finally,
tissue sections were counterstained with hematoxylin.
As primary antisera, polyclonal and monoclonal anti-
vWF antibodies (both Dako, Glostrup, Denmark) at a
dilution of 1:2,000 and 1:300, respectively, were used to
evaluate vWF in the endocardial endothelium. To confirm
Abbreviations and Acronyms
AF 5 atrial fibrillation
eNOS 5 endothelial nitric oxide synthase
GP Ib/IX 5 glycoprotein Ib/IX
GP IIb/IIIa 5 glycoprotein IIb/IIIa
IgG 5 immunoglobulin G
vWF 5 von Willebrand factor
Table 1. Biographical and Hemodynamic Data of Cardiac Patients
Diagnosis Mitral VD Aortic VD IHD ASD Heart Failure
Men/women 7/8 7/4 4/2 5/2 2/2
Age (yrs) 58 6 3.2 53 6 5 62 6 3.8 36 6 10.3 68 6 6.7
CI (l/min) 2.5 6 0.18 3.5 6 0.17 3.7 6 0.40 NA NA
LVEF (%) 63 6 3.3 68 6 4.3 57 6 8.9 67 6 1.6 39 6 6.2
LVEDD (mm) 55 6 2.8 59 6 3.4 54 6 2.3 38 6 0.8 62 6 4.8
AF (1/2) 12/3 1/10 0/6 1/6 2/2
Hypertension (%) 13 27 17 14 0
Diabetes (%) 13 9 17 0 25
Medications
Warfarin (%) 53 9 0 0 25
Aspirin (%) 40 27 50 0 25
Digoxin (%) 87 0 17 29 50
ACE inhibitor (%) 20 18 50 0 50
Ca antagonist (%) 13 36 50 14 25
Nitrates (%) 13 9 83 0 0
Diuretics (%) 53 9 0 0 100
Age and hemodynamic data are expressed as means 6 SEM.
ACE 5 angiotensin-converting enzyme; AF 5 atrial fibrillation; ASD 5 atrial septal defect; Ca 5 calcium; CI 5 cardiac
index; IHD 5 ischemic heart disease; LVEDD 5 left ventricular end-diastolic dimension; LVEF 5 left ventricular ejection
fraction; NA 5 not available; VD 5 valvular disease.
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the integrity of the endothelium, serial sections were also
immunostained for other endothelial cell markers using mono-
clonal antibodies against CD31 (Dako), CD34 (Nichirei,
Tokyo, Japan) and eNOS (Transduction Laboratories, Lex-
ington, Kentucky). Platelets on the endocardium were detected
by immunostaining with monoclonal antibodies against the
membrane receptors for vWF; glycoprotein (GP) Ib/IX
(PharMingen, San Diego, California) and GP IIb/IIIa
(Chemicon International Inc., Temecula, California). The
concentrations of these primary antisera were determined by
using isolated normal human platelets and human coronary
arteries isolated at autopsy. The specificity of immunostaining
was assessed by incubation with nonimmunized rabbit or
mouse serum instead of the primary antiserum.
Immunoelectronmicroscopy. Atrial tissue was fixed in a
mixture of 4% paraformaldehyde and 0.2% glutaraldehyde
for 4 h at room temperature. After the fixation, the tissue
was dehydrated with two washes (60 min each) in 70%
ethanol and was placed into LR White resin (Agar Scien-
tific Ltd., Essex, U.K.). After 1 h the LR White resin was
changed and the tissue left in it was placed on a rotary mixer
overnight. Following an additional change of resin for 1 h,
the tissue was embedded in a small gelatin capsule to avoid
oxygen and polymerized at 50°C for 24 h. Ultrathin resin
sections (110 nm) were cut on a Leica Ultracut R Mic-
rotome and collected on 200-mesh nickel grids. The im-
munogold labeling method was employed as previously
described (16). Briefly, grids were incubated serially on
droplets of the following solutions: 1) 5% normal goat
serum in phosphate-buffered saline containing 1% bovine
serum albumin (1% BSA/PBS, pH 8.2) for 10 min; 2)
polyclonal anti-vWF antibody (Dako) diluted at 1:500 in
1% BSA/PBS at 4°C overnight; 3) a series of three fresh
droplets of 1% BSA/PBS for 5 min each; 4) goat antirabbit
IgG, conjugated to 10-nm gold particles, diluted at 1:100 in
1% BSA/PBS for 1 h (British BioCell International, Cardiff,
United Kingdom); 5) a series of three fresh droplets of 1%
BSA/PBS for 5 min each followed by washing in distilled
water; and 6) 2% aqueous uranyl acetate for 20 min followed by
washing with distilled water and air drying. The sections were
examined using a JEM-1010 electron microscope (JEOL Ltd.,
Tokyo, Japan) operated at an accelerating voltage of 80 kV.
Histological analysis. Immunoreactivity for vWF and
platelet adhesion/thrombus formation in the endocardium
was semiquantitatively assessed by light microscopic obser-
vation. Immunostaining intensity for vWF in the endocar-
dium was graded in comparison with that in the endothe-
lium of intramyocardial vessels of the same sections (grade
1, only focal or little staining; grade 2, diffuse, weaker
staining; grade 3, similar staining and grade 4, stronger
staining). The grading was performed independently by two
observers without prior knowledge of the case histories. In
cases in which there was a discrepancy between the two
observers, the final score was determined by joint observa-
tion. Grades for different sections from the same atrial
appendage were averaged to give a single value. The degree
of platelet adhesion/thrombus formation in the endocar-
dium was graded according to the distribution and nature of
adhered platelets positive to GP Ib/IX and GP IIb/IIIa in
each atrial appendage (grade 1, no adhesion; grade 2, a few
patchy adhesions; grade 3, multiple and/or widespread
adhesions and grade 4, thrombi containing other blood cell
types). Clotted blood with no attachment to the endocar-
dium was sometimes found in autopsy cases and was
excluded as a postmortem artifact.
Statistical analysis. Immunohistochemical grades for vWF
in the endocardium were categorized into four ranks (1, #2,
#3, and #4) in each atrial appendage and were compared
among different patient groups by the Kruskal-Wallis rank
test. After global testing, a multiple-comparison procedure
with Student-Newman-Keuls test was performed in each
pairwise comparison. The relationship between the immu-
nohistochemical grade for vWF and the degree of platelet
adhesion/thrombus formation in the endocardium was ex-
amined by Spearman rank correlation. The incidence was
compared among different groups by chi-square analysis.
Values of p , 0.05 were considered significant.
RESULTS
Immunoreactivity for vWF in the endocardium varied
widely among individual atrial appendages, whereas appar-
ent immunoreactivity for vWF was consistently seen in the
endothelium of the intramyocardial vessels of the same atrial
tissues as well as in isolated platelets (Fig. 1). In noncardiac
Figure 1. Typical examples of immunohistochemistry for von Willebrand
factor in right and left atrial appendages from patients with noncardiac
disease (N; 63 years old, male), mitral valvular stenosis (MS; 53 years old,
female), and end-stage heart failure (HF; 80 years old, male), respectively.
The latter two cases were accompanied by atrial fibrillation. RAA and
LAA indicate right and left atrial appendages, respectively. Bar 5 200 mm.
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patients with none of the high-risk predictors for thrombo-
embolism, only focal or little immunoreactivity for vWF was
seen in the endocardium of both right and left atrial
appendages (Fig. 1, N). On the other hand, apparent
immunoreactivity for vWF was extensively seen in the
endocardium of atrial appendages of most cardiac patients
examined. Particularly, stronger immunoreactivity for vWF
in the endocardium compared with that in the endothelium
of intramyocardial vessels was seen in the left, but not in the
right, atrial appendages of patients with mitral valvular
disease (Fig. 1, MS), and in both right and left atrial
appendages of patients with end-stage heart failure (Fig. 1,
HF). In contrast to the varying immunoreactivity for vWF
in the endocardium, an apparent immunoreactivity for
CD31 and CD34 in the endocardium was preserved in most
cases of both cardiac and noncardiac patients (Fig. 2A; vWF
vs. CD31). Immunoreactivity for endothelial nitric oxide
synthase (eNOS) in the endocardium was apparently seen in
most atrial appendages of noncardiac patients, but was
inconsistent in atrial tissues of cardiac patients (Fig. 2A;
eNOS). Immunoelectron microscopy showed that positive
gold labeling for vWF antigen was observed mainly in
vesicles within the endocardial endothelium and, to a lesser
extent, in the subendothelium (Fig. 2B). Few gold particles
were observed alongside the luminal surface of the plasma
membrane of the endothelium. No specific staining was
seen in the negative control sections (data not shown).
The immunohistochemical grade for vWF in the endo-
cardium was summarized according to the underlying heart
disease (Fig. 3). There was a significantly higher immuno-
histochemical grade for vWF in the endocardium of both
right and left atrial appendages of all cardiac patient groups
Figure 2. (A) Typical examples of immunohistochemistry for endothelial cell markers including von Willebrand factor, CD31 and eNOS in atrial
appendages from noncardiac (N) and cardiac patients (HD), between which the immunoreactivity for vWF in the endocardium differed greatly. No specific
staining was seen in control sections incubated with nonimmunized immunoglobulin (C). Bar 5 100 mm. (B) Electron micrographs of left atrial appendage
of a cardiac patient, which had been stained with the immunogold method using polyclonal anti-vWF antibody. Gold particles (arrows) are present in
vesicles within the endocardial endothelium and in the subendothelium. EC 5 endothelial cell; L 5 lumen. Original magnification 312,000.
Figure 3. Distribution of immunohistochemical grades for von Willebrand
factor in the endocardium of atrial appendages according to the underlying
cardiac pathogenesis. Immunohistochemical grades for von Willebrand
factor were averaged to give a single value to each atrial appendage and
were categorized into four ranks (1, #2, #3 and #4). Closed symbols
indicate cases of mitral valvular disease in which right and left atrial
appendages were paired. There was a significant difference among different
groups by Kruskal-Wallis rank test (p , 0.01). Each pairwise comparison
was performed by Student-Newman-Keuls test for multiple comparisons.
†p , 0.01 vs. all groups with underlying cardiac pathogenesis other than
IHD (p , 0.05). *p , 0.05; **p , 0.01. ASD 5 atrial septal defect;
AVD 5 aortic valvular disease; HF 5 end-stage heart failure; IHD 5
ischemic heart disease; MVD 5 mitral valvular disease; N 5 nondiseased
heart; NS 5 not significant.
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than in those of noncardiac patients. Furthermore, among
the cardiac patient groups, the left, but not the right, atrial
appendages of patients with mitral valvular disease and both
right and left atrial appendages of patients with end-stage
heart failure showed a significantly higher immunohisto-
chemical grade for vWF in the endocardium compared with
that of the right appendages of any other patient groups.
However, a similar immunohistochemical grade for vWF in
the endocardium was seen in the atrial appendages of
cardiac patients with and without concomitant AF (mean
values; 2.33 [n 5 16] vs. 2.44 [n 5 25] for right atria, 3.63
[n 5 12] vs. 3.25 [n 5 4] for left atria). In addition, this
vWF grade was not correlated with any clinical and hemo-
dynamic variables including age, hypertension, diabetes,
cardiac index, left ventricular ejection fraction, and left
ventricular end-diastolic dimension or with any medications
before heart surgery.
No macroscopic thrombus formation was observed in any
atrial appendages examined. Immunohistochemistry for
platelet GP Ib/IX or GP IIb/IIIa showed various degrees of
platelet adhesion/thrombus formation in more than half the
atrial appendages of cardiac patients with and without AF
(Fig. 4, shown for GP Ib/IX). Adhered platelets in the
endocardium also had apparent immunoreactivity for vWF
and CD31, but were found only in limited sites with the
endocardial endothelium deficient in immunoreactive
eNOS and CD34 (Fig. 4, shown for eNOS). Only patchy or
no platelet adhesions were found in the endocardium of
atrial appendages from noncardiac patients.
In order to explore the possible role of increased endo-
cardial vWF in thrombogenicity in atrial appendages of
cardiac patients, the degree of platelet adhesion/thrombus
formation was plotted as a function of the immunohisto-
chemical grade for endocardial vWF in each atrial append-
age (Fig. 5). A significant correlation between both variables
was seen only when cases that had been treated with
warfarin, alone or in combination with aspirin, (closed
symbols in Fig. 5) were excluded (r 5 0.52, p , 0.01 [n 5
30] by Spearman rank correlation). No platelet adhesion/
thrombus formation graded at 3# was seen in warfarin-
treated cases (n 5 22) irrespective of the immunohisto-
chemical grade for vWF. These cases consisted mainly of
atrial appendages from mitral valvular disease patients with
concomitant AF. On the other hand, the degree of platelet
adhesion/thrombus formation was similar in aspirin-
treated, but not warfarin-untreated cases nor aspirin or
warfarin-treated cases (grade $3; 3/10 vs. 10/20, p 5 NS).
DISCUSSION
It has been well established that vWF in the subendothe-
lium or plasma is required for platelet adherence to deen-
dothelialized vessel walls (8–10), which is mediated by the
interaction with two platelet surface receptors, GP Ib/IX
and GP IIb/IIIa (17,18). The present study demonstrated
increased immunoreactive vWF in the endocardium of atrial
appendages from both AF and non-AF patients with a
variety of underlying heart diseases. This increased immu-
noreactive vWF in the endocardium was significantly cor-
related with the degree of platelet adhesion/thrombus for-
mation detected microscopically as positive to GP Ib/IX or
GP IIb/IIIa. These results suggest a possible role of in-
creased endocardial platelet adhesion molecule vWF in
thrombogenesis in the human atrial appendage.
Figure 4. Immunohistochemical localization and patterns of platelet ad-
hesion/thrombus formation in atrial appendages of cardiac patients. Im-
munohistochemistry for glycoprotein Ib/IX and endothelial nitric oxide
synthase in serial sections is shown in three typical cases. P 5 patchy
platelet adhesion; T 5 thrombus; W 5 widespread platelet adhesion.
Bar 5 100 mm.
Figure 5. Relation between the immunohistochemical grade for von
Willebrand factor (vWF) and the degree of platelet adhesion/thrombus
formation in the endocardium. Each symbol indicates a right or left atrial
appendage obtained from a cardiac patient. There was a significant
correlation between the two variables (r 5 0.52, p , 0.01 by Spearman
rank correlation) only when the cases who had received warfarin-treatment
(closed symbols) were excluded.
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Immunoreactive vWF in the endocardial endothelium.
In the present study, it is noteworthy that only focal or little
immunoreactive vWF was found in the endocardium of
noncardiac patients with none of the clinical high-risk
predictors for thromboembolism, whereas vWF was appar-
ent in the endothelium of intramyocardial vessels of the
same cases. We confirmed that immunoreactivity for other
endothelial cell markers, CD31, CD34 and eNOS, was
maintained in the endocardial endothelium as well as in the
vessel endothelium. Our observations suggest that in non-
cardiac patients, the endocardial endothelium of the atrial
appendage is selectively deficient in vWF, which has been
used as an endothelial cell marker in human vessels (19,20).
However, this is not surprising because Yamamoto et al.
(21) have recently reported that vWF is differentially ex-
pressed in endothelial cells among different tissues or organs
in mice.
On the other hand, increased immunoreactivity for vWF
in the endocardium was found particularly in the left,
compared with the right, atrial appendage of patients with
mitral valvular disease and in both right and left atrial
appendages of patients with end-stage heart failure (Fig. 3),
but irrespective of the presence of AF. Previously, Rabino-
vitch et al. (12) had also shown increased immunostaining
for vWF in the pulmonary vessel endothelium of patients
with pulmonary hypertension. These immunohistochemical
data suggest that increased vWF antigen in the vessel
endothelium and atrial endocardium is associated with
abnormal hemodynamic conditions. In the present study,
the integrity of the overlying endothelium was confirmed in
most areas with abundant vWF antigen by immunostaining
for several endothelial cell markers (Fig. 2). In addition, an
electron microscopic observation showed that vWF antigen
was located in vesicles within the endocardial endothelium
and subendothelium. This is consistent with evidence that
vWF is synthesized in endothelial cells and constitutively
secreted into both luminal and abluminal sides of those cells
(19,22). Because it has been shown in an in vitro study that
endothelial cells do not bind or uptake exogenous vWF
(23), abundant vWF antigen in the endocardium of over-
loaded atrial appendage most likely reflects its increased
synthesis in the overlying endothelium. Nevertheless, the
present study did not determine the exact origin of the vWF
deposited in the subendothelium. We cannot exclude the
possibility that mechanical overload in the atrial walls may
damage the superficial endothelial cell layers, allowing
deposition of plasma-derived vWF into the subendothe-
lium.
vWF and thrombogenesis in the endocardium. An inti-
mate relationship between increased immunoreactive vWF
in the endocardium and platelet adhesion/thrombus forma-
tion (Fig. 5) supports the possible role of the endocardial
vWF in increased thrombogenicity in atrial appendages of
patients with a variety of underlying cardiac pathogeneses.
However, platelet adhesion in the endocardium was found
only in limited sites in which the overlying endothelium was
deficient in immunoreactive eNOS and CD34 (Fig. 4). This
is consistent with the concept that platelet adhesion to the
vessel wall requires endothelial injury, which would induce
the secretion of vWF into the lumen and subendothelium
and subsequently expose abundant vWF to circulating
platelets (8–11,22). Alternatively, in most areas with appar-
ent eNOS staining in the overlying endothelium, the
absence of platelet adhesion may be in part explained by the
release of endothelium-derived factors, including nitric
oxide and prostacyclin, that have been shown to inhibit
platelet adhesion/aggregation (24).
Previous studies using transesophageal echocardiography
have shown that a rheologic factor, blood stasis, is important
in thrombogenesis in the atrial appendages of both AF and
non-AF patients with underlying cardiac pathogenesis
(2,3). Fatkin et al. (25) have estimated the shear rate of
blood at the orifice of the left atrial appendage to be 50 to
150 s21 in patients with AF. Although it has been experi-
mentally demonstrated that vWF plays a major role in
platelet adhesion at a high shear rate (8–10), there is
evidence suggesting that vWF can mediate platelet adhesion
to the subendothelium or vWF-coated coverslips at shear
rates as low as 50 to 650 s21 (8,10,18,26,27). In addition,
Badimon et al. (26) have observed that platelet adhesion to
subendothelium at longer exposure times (20 to 30 min)
reaches similar plateau levels at shear rates ranging from 212
to 3,380 s21. Thus, it is possible that under in vivo
conditions, chronic exposure of subendothelial vWF to
circulating platelets would induce stable platelet adhesion
even at low shear rates.
Effects of antithrombotic therapy. In the present study,
we observed platelet adhesion/thrombus formation at the
tissue level in more than half the atrial appendages of the
cardiac patients examined. Although the study population
was too small to compare the incidence of thrombus
formation among different patient groups, it was noted that
in cases with warfarin treatment, but not in cases with
aspirin treatment alone, neither multiple nor widespread
platelet adhesion/thrombus formation (graded at #3) was
found in any atrial appendages examined (Fig. 5). This
observation is consistent with the results of clinical trials in
which warfarin was more effective than aspirin in preventing
cardioembolic events in patients with nonrheumatic AF
(1,5,28). The antithrombotic effect of full-dose warfarin,
but not of aspirin, in patients with AF has also been
confirmed by the reduced plasma levels of fibrin D-dimer
and beta-thromboglobulin (29). Aspirin inhibits platelet
aggregation but not direct attachment to the subendothe-
lium, which occurs mostly via fibrinogen (8,30). However,
the inhibitory effects of aspirin on platelet aggregation in
response to agonists are limited (31), and shear-induced
platelet aggregation mediated by vWF is resistant to aspirin
(32). Therefore, it is possible that, in aspirin-treated pa-
tients, increased vWF in the endocardium may act as an
alternative mechanism for aspirin-sensitive, fibrinogen-
dependent platelet aggregation.
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Conclusions. The present study demonstrates, for the first
time, increased immunoreactive vWF in the endocardial
endothelium and its intimate relationship to thrombogen-
esis detected microscopically in atrial appendages of patients
with underlying cardiac pathogenesis, irrespective of the
presence of concomitant AF. The increased vWF in asso-
ciation with the disruption of the endocardial endothelium
would contribute to the initiation of thrombogenesis by
promoting platelet adhesion/aggregation on the endocardial
surface, whereas a rheologic factor is thought to be required
for further growth of the thrombus into the atrial lumen.
Our results suggest that, independent of the presence of AF,
vWF levels in the endocardial endothelium may modulate
local thrombogenicity in the human atrial appendage.
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